Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2004

01-07-2004 | Review Article

Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients

Authors: Cesare Gridelli, Matti Aapro

Published in: Supportive Care in Cancer | Issue 7/2004

Login to get access

Abstract

With old age comes declining organ function, cognitive impairment, increased likelihood of comorbid conditions and multiple prescription and nonprescription pharmacotherapy. These issues are particularly relevant in elderly cancer patients, who commonly receive combination chemotherapy and supportive care agents along with radiation therapy and surgery. This situation can complicate medical care, particularly since over half of all cancers occur in those aged over 65 years. The 5-HT3-receptor antagonists as a class are highly effective antiemetics and are currently considered the gold standard for treatment of chemotherapy- and radiotherapy-induced nausea and vomiting. However, these agents do possess different pharmacologic properties, such as varying terminal half lives, routes of metabolism and selectivity for 5-HT3 receptors. These differences may have an impact on efficacy (e.g., duration of action of the drug) safety (e.g., the risk of drug interactions and potential adverse effects), and simplicity of the dosing regimen. The focus of this review is on some of the pertinent issues of 5-HT3 antagonists relating to elderly cancer patients.
Literature
1.
Aapro MS (1993) Methodological issues in antiemetic studies. Invest New Drugs 11:243–253PubMed
2.
Aapro M, Bourke J (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. Eur J Cancer 39:927–931CrossRefPubMed
3.
Addelman M, Erlichman C, Fine S, Warr D, Murray C (1990) Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. J Clin Oncol 8:337–341PubMed
4.
Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1995) Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626–631CrossRefPubMed
5.
Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127–132PubMed
6.
Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J (1991) QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83:1888–1894
7.
Anonymous (2000) Cytochrome P450. http://​www.​anaesthetist.​com/​physiol/​basics/​metabol/​cyp/​cyp.​htm
8.
Ashanani F, Heys SD, Eremin O (1999) The management of cancer in the elderly. J R Coll Surg Edinb 44:2–10PubMed
9.
Audhuy B, Cappelaere P, Marin M, et al (1996) A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A:807–813CrossRefPubMed
10.
Aventis Pharmaceuticals (2000) Anzemet (dolasetron mesylate). Prescribing information
11.
Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–258
12.
Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557–566PubMed
13.
Blower P (1990) The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 26 [Suppl 1]:S8–11
14.
Blum RA, Majumdar A, McCrea J, et al (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25:1407–1419CrossRefPubMed
15.
Boike SC, Ilson B, Zariffa N, Jorkasky DK (1997) Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 54:1172–1176
16.
Boxenbaum H, Gillespie T, Heck K, Hahne W (1992) Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693–701
17.
Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB (1999) Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 24:1–4CrossRefPubMed
18.
Carmichael J, Bergstrom B (2002) The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy (abstract). 14th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC), 23–26 June 2002, Boston, MA
19.
Carmichael J, Cantwell BMJ, Edwards CM, et al (1989) A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with antiemetic response. Cancer Chemother Pharmacol 24:45–49PubMed
20.
Carmichael J, Philip PA, Forfar C, Harris AL (1995) An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 37:134–138CrossRefPubMed
21.
Catterson ML, Preskorn SH, Martin RL (1997) Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Geriatr Psychiatry 20:205–218
22.
23.
Cowan JD, Neidhart J, McClure S, et al (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83:1077–1084
24.
Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol 30:581–588PubMed
25.
Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative care. Support Care Cancer 9:442–451
26.
Dixon CM, Colthup PV, Serabjit-Singh CJ, et al (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–1230PubMed
27.
Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113–119PubMed
28.
Dretakis KE, Dretakis EK, Papakitsou EF, Psarakis S, Steriopoulos K (1998) Possible predisposing factors for the second hip fracture. Calcif Tissue Int 62:366–369CrossRefPubMed
29.
Eastell R, Reid DM, Compston J, et al (2001) Secondary prevention of osteoporosis—when should a non-vertebral fracture be a trigger for action? Q J Med 94:575–597CrossRef
30.
Ewer MS, Benjamin RS (1997) Cardiac complications. In: Holland JF, Bast RC, Morton DL, et al (eds) Cancer medicine, 4th edn. Williams and Wilkins, Baltimore, pp 3197–215
31.
Extermann M (2002) Comorbidity and geriatric assessment in the elderly patient over the age of 70. Tumori 88 [Suppl 1]:S9
32.
Extermann M, Aapro M (2000) Assessment of the older cancer patient. Hematol Oncol Clin North Am 14:63–77PubMed
33.
Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400–449PubMed
34.
FDA (2003) Background information regarding EMEND(tm) (aprepitant) capsules. Gastrointestinal Drugs Advisory Committee, 6 March 2003, briefing Information. http://​www.​fda.​gov/​ohrms/​dockets/​ac/​03/​briefing/​3928b1.​htm
35.
Fukui H, Imai K, Chikaato M, Yamamoto M, Sato S (1991) Visceral afferent fibers and peripheral 5-HT3 receptor mediate cisplatin-induced emesis in dogs (abstract). Jpn J Pharmacol 55 [Suppl 1]:152P
36.
Gaedigk A (2000) Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 38:61–68PubMed
37.
Gilbert CJ, Petros WP, Vredenburgh J, et al (1998) Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 42:497–503
38.
GlaxoSmithKline (1999) Zofran (ondansetron hydrochloride) tablets and Injection. Prescribing information
39.
Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994PubMed
40.
Gridelli C, Perrone F, Gallo C, et al (2003) Chemotherapy for elderly patients with advanced non small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study phase III randomized trial. J Natl Cancer Inst 95:362–372CrossRefPubMed
41.
Hesketh P, Navari R, Grote T, et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 14:2242–2249PubMed
42.
Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247–255PubMed
43.
Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS (1999) Underrepresentation of patients aged 65 years or older in cancer-treatment trials. N Engl J Med 341:2061–2067CrossRefPubMed
44.
Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805–810PubMed
45.
Jörgensen T, Johansson S, Kennerfalk A, Wallander M-A, Svärdsudd K. (2001) Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35:1004–1009CrossRefPubMed
46.
Kaiser R, Sezer O, Papies A, et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811CrossRefPubMed
47.
Keefe DL (2000) Cardiovascular emergencies in the cancer patient. Semin Oncol 27:244–255PubMed
48.
Keefe DL (2002) The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist 7:65–72PubMed
49.
Kees F, Färber L, Bucher M, Mair G, Mörike K, Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 52:705–707CrossRefPubMed
50.
Kleisbauer J-P, García-Girón C, Antimi M, Azevedo MC, Blames H, Massuti-Sureda B, Contu A, Luque A, Pellier P (1998) Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs 9:387–332PubMed
51.
Koriech OM (1995) Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol 7:371–372
52.
Kris MG, Cubeddu LX, Gralla RJ, et al (1996) Are more antiemetic trials with placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78:2193–2198CrossRefPubMed
53.
Laszlo J (1983) Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J (ed) Antiemetics and cancer chemotherapy. Williams and Wilkins, Baltimore London, pp 1–5
54.
Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340PubMed
55.
Lorenz C, Eickhoff C, Bauman F, et al (2000) Does ondansetron affect the metabolism of cyclophosphamide? Int J Clin Pharmacol Ther 38:143–144
56.
Love RR, Leventhal H, Easterling DV, Nerenz DR (1989) Side effects and emotional distress during cancer chemotherapy. Cancer 63:604–612PubMed
57.
Lowenthal RM, Eaton K (1996) Toxicity of chemotherapy. Hematol Oncol Clin North Am 10:967–990PubMed
58.
Marez D, Legrand M, Sabbagh N, et al (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 56 alleles, their frequencies and evolution. Pharmacogenetics 7:193–202PubMed
59.
Merck (2003) Emend, prescribing information. Merck and Company, Whitehouse Station, NJ
60.
Miller H, Mullaly K, Quigley J, Baran R, Coop AJ (2002) Use of 5-HT3 receptor antagonists in patients at risk of QTc prolongation: results of a retrospective claims based analysis (abstract P-364D). 37th American Society of Health System Pharmacists, 8–12 December, Atlanta, GA
61.
Minton NA (1994) Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists. Br J Clin Pharmacol 37:525–530PubMed
62.
Monfardini S, Sorio R, Boes GH, Kaye S, Serraino D (1995) Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76:333–338PubMed
63.
Nelson DR, Thomas DR (1989) [3H]-BRL 43694 (granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 38:1693–1695PubMed
64.
Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA (1993) BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 32:729–735
65.
Novartis Pharmaceuticals (1997) Navoban (tropisetron). Product information
66.
O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres. Can Med Assoc J 149:296–302
67.
Perez EA, Hesketh P, Sandbach J, et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760PubMed
68.
Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C (1998) Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4:52–58PubMed
69.
Pignon J-P, Arriagada R, Ihde DC, et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618–1624PubMed
70.
Ramamoorthy Y, Suh N, Tyndale RF, Sellers EM (2000) Differentially altered metabolism and inhibition of CYP2D6*10 (abstract). Clin Pharmacol Ther 67:121
71.
Roche Laboratories (2000) Kytril (granisetron hydrochloride) tablets and injection. Prescribing information
72.
Roila F, Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29:95–109
73.
Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332:1004–1014PubMed
74.
Ruff P, Paska W, Goedhals L, et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113–118PubMed
75.
Sanwald P, David M, Dow J (1996) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 24:602–609PubMed
76.
Satariano WA (1993) Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol 330:1–11PubMed
77.
Seidman A, Hudis C, Pierri MK, et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215–1221CrossRefPubMed
78.
Shah A, Lanman R, Bhargava V, Weir S, Hahne W (1995) Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 16:177–189
79.
Sheehy CM, Perry PA, Cromwell SL (1999) Dehydration: biological considerations, age-related changes, and risk factors in older adults. Biol Res Nurs 1:30–37PubMed
80.
Sparano JA (2002) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28 [Suppl 3]:20–27
81.
Stanford BJ, Stanford SC (1999) Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 13:313–317PubMed
82.
Upward JW, Arnold BDC, Link C, Pierce DM, Allen A, Tasker TCG (1990) The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 26 [Suppl 1]:S12–S15
83.
Van Wijngaarden I, Tulp MTM, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188:301–312PubMed
84.
Wei JY (1995) Cardiovascular comorbidity in the older cancer patient. Semin Oncol 22 [Suppl 1]:9–10
85.
Yancik R (1997) Cancer burden in the aged. An epidemiologic and demographic overview. Cancer 80:1273–1283CrossRefPubMed
86.
Yancik R, Ries LAG (2000) Aging and cancer in America. Hematol Oncol Clin North Am 14:17–23PubMed
Metadata
Title
Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients
Authors
Cesare Gridelli
Matti Aapro
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2004
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0596-3

Other articles of this Issue 7/2004

Supportive Care in Cancer 7/2004 Go to the issue

Original Article

Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies

Review Article

Quality of life of survivors of testicular germ cell cancer: a review of the literature

Society News

July 2004

Original Article

Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis

Short Communication

Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy

Original Article

Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits